Skip to main content

and
  1. Article

    Open Access

    Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

    Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine c...

    Xavier Duval, Adrian Caplanusi, Henri Laurichesse in BMC Infectious Diseases (2012)

  2. Article

    Open Access

    Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

    Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity betwe...

    Odile Launay, Xavier Duval, Serge Fitoussi, Wolfgang Jilg in BMC Infectious Diseases (2013)

  3. Article

    Open Access

    Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

    The pandemic potential of avian influenza A/H5N1 should not be overlooked, and the continued development of vaccines against these highly pathogenic viruses is a public health priority.

    Paul Gillard, Daniel Wai Sing Chu, Shinn-Jang Hwang in BMC Infectious Diseases (2014)